{"id":527255,"date":"2021-08-12T08:03:58","date_gmt":"2021-08-12T12:03:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/"},"modified":"2021-08-12T08:03:58","modified_gmt":"2021-08-12T12:03:58","slug":"dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/","title":{"rendered":"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update"},"content":{"rendered":"<h2>\nConference Call and Webcast Today at 4:30 p.m. Eastern Time<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Aug.  12, 2021  (GLOBE NEWSWIRE) &#8212; Dar\u00e9\u00a0Bioscience, Inc. (NASDAQ: DARE), a leader in women\u2019s health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update.<\/p>\n<p align=\"justify\">\u201cThis has been, and continues to be, an incredibly productive year for Dar\u00e9,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cConsistent with our guidance, we submitted our New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June. Our NDA was accepted for filing and received Priority Review with a PDUFA target date of December 7, 2021. This year we also commenced the Phase 2b RESPOND study of Sildenafil Cream, 3.6%, a potential first-in-category product in development to treat female sexual arousal disorder, a physiological condition for which there are no FDA approved products. In June, we announced positive topline results from our Phase 1 study of DARE-HRT1, a novel intravaginal ring designed to deliver bio-identical hormones which is being developed to treat vasomotor symptoms and the genitourinary syndrome commonly associated with menopause. And finally, we reported two new sources of non-dilutive funding for two of our programs \u2013 first, a grant intended to support the continued development of DARE-LARC1 over more than five years through the non-clinical proof of principle work, and second, a collaboration with the National Institutes\u00a0of Health\u2019s\u00a0Eunice Kennedy Shriver\u00a0National Institute of Child Health and Human Development providing financial and operational support for the conduct of a pivotal Phase 3 clinical trial of Ovaprene<sup>\u00ae<\/sup>, an investigational hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Portfolio Accomplishments and Management Expectations for 2021-2022<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>DARE-BV1: <\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Dar\u00e9 innovation: Novel, investigational thermosetting bioadhesive hydrogel formulated with clindamycin phosphate 2% as a first-line, single-administration treatment for bacterial vaginosis.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>4Q 2020<\/strong>: Successfully completed DARE-BVFREE Phase 3 clinical study.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>June 2021<\/strong>: Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>2021 Prescription Drug User Fee Act (PDUFA) goal date<\/strong>: NDA accepted and received Priority Review with a PDUFA target date of December 7, 2021.<\/li>\n<li style=\"text-align:justify\">\n              <strong>2021<\/strong>: Execute and announce commercialization strategy for DARE-BV1 in the U.S. to support a robust market introduction in 2022, if approved.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>Sildenafil Cream, 3.6%: <\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Dar\u00e9 innovation: Proprietary, investigational cream formulation of sildenafil, the active ingredient in Viagra\u00ae, for topical administration to treat female sexual arousal disorder (FSAD).<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>1Q 2021<\/strong>: Commenced Phase 2b RESPOND clinical study.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>2021<\/strong>: Ongoing enrollment in Phase 2b RESPOND clinical study.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">FSAD is a physiological condition characterized by the inability to attain or maintain sufficient genital arousal during sexual activity and, of the various types of female sexual dysfunction disorders, is most analogous to erectile dysfunction in men.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">FSAD represents a significant unmet need, with an estimated 10 million women in the U.S. experiencing distress from symptoms of low or no sexual arousal and actively seeking treatment.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>DARE-HRT1:<\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Dar\u00e9 innovation: Unique, investigational 28-day intravaginal ring (IVR) containing bio-identical estradiol and bio-identical progesterone for the treatment of vasomotor symptoms and genitourinary syndrome associated with menopause.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>June 2021<\/strong>: Reported positive topline data of Phase 1 clinical study.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>Ovaprene:<\/strong><br \/>\n          <\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Dar\u00e9 innovation: Novel, investigational hormone-free monthly intravaginal contraceptive whose\u00a0U.S.\u00a0commercial rights are under a license agreement with Bayer.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>3Q 2021<\/strong>: <\/p>\n<ul type=\"square\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Announced a Collaborative Research and Development Agreement (CRADA) for a pivotal Phase 3 clinical study of Ovaprene in the U.S.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">The CRADA is with the <em>Eunice Kennedy Shriver<\/em> National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">The CRADA will allow Dar\u00e9 to leverage the contraceptive clinical trial expertise of NICHD while also sharing the costs of the Phase 3 clinical study with NICHD.\u00a0\u00a0 Dar\u00e9 agreed to contribute $5.5 million toward the total estimated cost to conduct the study and to provide clinical supplies of Ovaprene.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>4Q 2021<\/strong>: Submit Investigational Device Exemption (IDE) to the FDA for a pivotal Phase 3 clinical study in the U.S.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>2022: <\/strong>Commence the pivotal Phase 3 clinical study.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>DARE-VVA1:<\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt;text-align:justify\">Dar\u00e9 innovation: Proprietary, investigational formulation of tamoxifen for vaginal administration to treat vulvar and vaginal atrophy (VVA) in women with or at risk for hormone-receptor positive breast cancer.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n              <strong>2H 2021:<\/strong> Initiate Phase 1 clinical study in Australia.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Financial Highlights for period ended June 30, 2021<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt;text-align:justify\">Cash and cash equivalents: $9.1 million at June 30, 2021, compared to $4.7 million at December 31, 2020.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">Net cash from financing activities during the six months ending June 30, 2021 was approximately $24.6 million and included net proceeds from sales of common stock under the company\u2019s at-the-market offering program and equity line and warrant exercises.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">General and administrative expenses were approximately $1.8 million in 2Q 2021, as compared with $1.6 million in 2Q 2020, with the increase reflecting higher personnel costs and stock-based compensation expense.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">Research and development expenses were approximately $7.3 million in 2Q 2021, as compared to approximately $5.5 million in 2Q 2020. The $1.8 million increase was due primarily to increases in expenses related to clinical trial and other development and regulatory affairs activities for Sildenafil Cream, 3.6%, DARE-BV1, Ovaprene and DARE-HRT1.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">Comprehensive loss for 2Q 2021 was approximately $9.2 million, as compared to approximately $7.1 million for 2Q 2020.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Recent Financial Developments<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt;text-align:justify\">Between July 1, 2021 and August 10, 2021, Dar\u00e9 received additional cash of approximately $25.4 million (net of fees) from sales of common stock under the company\u2019s at-the-market offering program.<\/li>\n<li style=\"text-align:justify\">In July 2021, Dar\u00e9 received an initial cash payment of $11.45 million in non-dilutive grant funding to support the non-clinical development of DARE-LARC1. The entire grant award is for up to $48.95 million and future payments are contingent upon the DARE-LARC1 program\u2019s achievement of specified development and reporting milestones.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"margin-bottom:12pt;text-align:justify\">As of August 10, 2021, approximately 70.5 million shares of Dar\u00e9 common stock were outstanding.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Conference Call<\/strong>\n      <\/p>\n<p align=\"justify\">Dar\u00e9 will host a conference call and live webcast today at\u00a04:30 p.m. Eastern Time\u00a0to review the company&#8217;s financial results for the quarter ended June 30, 2021 and to provide a company update.<\/p>\n<p align=\"justify\">To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 5286254. The live webcast can be accessed under \u201cPresentations, Events &amp; Webcasts&#8221; in the Investors section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hHjMBhq2g5mBpiJ7kYFdwufi8gr1ayt3ogVRleFtW1LMk9i5ebIieQgQC1NAPQ0h_uIK3nDWKqErJV-jfka7Ik7PA-DBa61PXeDCx27OuGs=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/ir.darebioscience.com<\/a>. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 5286254. The call and webcast replay will be available until\u00a0August 26, 2021.<\/p>\n<p align=\"justify\">\n        <strong>About Dar\u00e9 Bioscience<\/strong>\n      <\/p>\n<p align=\"justify\">Dar\u00e9 Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women\u2019s health. The company\u2019s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.<\/p>\n<p align=\"justify\">Dar\u00e9\u2019s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene\u00ae, a novel, hormone-free monthly contraceptive candidate whose\u00a0U.S.\u00a0commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra\u00ae; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about Dar\u00e9\u2019s full portfolio of women\u2019s health product candidates, and mission to deliver differentiated therapies for women, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w-JkGjx7c1ocVgGkXJalONQw5Nu_gML75jH6a9y6i8KE9kt_dGX2U8yr-O5gl6enfEKLHXuyT16DDcQGfG_0TfSXp2Jm_b-Dt3rg18kHbuQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.darebioscience.com<\/a>.<\/p>\n<p align=\"justify\">Dar\u00e9 may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hHjMBhq2g5mBpiJ7kYFdwufi8gr1ayt3ogVRleFtW1I_GW95E8laiSoTlSHQtHYq6HwJoxL8EQfETQAgdDW1IJsvSeZ2BNNwuL4w4eF_gDBZEoAovqwuHpPefl7ejemd\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/ir.darebioscience.com<\/a>),\u00a0SEC\u00a0filings, press releases, public conference calls and webcasts. Dar\u00e9 will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Dar\u00e9 posts on its investor relations website or through social media channels may be deemed to be material information. Dar\u00e9 encourages investors, the media, and others interested in the company to review the information Dar\u00e9 posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Dar\u00e9\u2019s website mentioned above.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Dar\u00e9 cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201ctend to,\u201d or the negative version of these words and similar expressions. In this press release, forward-looking statements include, but are not limited to, statements relating to the market opportunity and commercial potential for Dar\u00e9\u2019s product candidates and management\u2019s expectations for Dar\u00e9\u2019s product candidates in 2021 and 2022, including anticipated timing for the conduct of clinical trials, topline and other clinical trial data readouts, IDE submissions, potential FDA review and approval, and a potential commercial launch of DARE-BV1. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Dar\u00e9\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risk and uncertainties related to: Dar\u00e9\u2019s ability to raise additional capital when and as needed to advance its product candidates and continue as a going concern; the effects of the COVID-19 pandemic on Dar\u00e9\u2019s operations, financial results and condition, and ability to achieve current plans and objectives, including the potential impact of the pandemic on Dar\u00e9\u2019s ability to timely enroll, conduct and report results of its clinical trials and on the ability of third parties on which Dar\u00e9 relies to assist in the conduct of its business, including its clinical trials, to fulfill their contractual obligations to Dar\u00e9; Dar\u00e9\u2019s ability to develop, obtain regulatory approval for, and commercialize its product candidates; the failure or delay in starting, conducting and completing clinical trials or obtaining FDA or foreign regulatory approval for Dar\u00e9\u2019s product candidates in a timely manner; Dar\u00e9\u2019s ability to design and conduct successful clinical trials, to enroll a sufficient number of patients, to meet established clinical endpoints, to avoid undesirable side effects and other safety concerns, and to demonstrate sufficient safety and efficacy of its product candidates;<\/em><br \/>\n        <em>the risk that positive findings in early clinical and\/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and\/or nonclinical studies of that candidate; the risk that developments by competitors make Dar\u00e9\u2019s product candidates less competitive or obsolete; failure of Dar\u00e9\u2019s product candidates, if approved, to gain market acceptance or obtain adequate coverage from third-party payers; Dar\u00e9\u2019s ability to retain its licensed rights to develop and commercialize a product candidate; Dar\u00e9\u2019s ability to satisfy the monetary obligations and other requirements in connection with its exclusive, in-license agreements covering the critical patents and related intellectual property related to its product candidates; the risks that the license agreement with Bayer may not become effective and, if it becomes effective, that future payments to Dar\u00e9 under the agreement may be significantly less than the anticipated or potential amounts; Dar\u00e9\u2019s failure to timely establish or leverage third-party partnerships or collaborations to commercialize its product candidates, if approved; Dar\u00e9\u2019s dependence on third parties to conduct clinical trials and manufacture clinical trial material; Dar\u00e9\u2019s ability to adequately protect or enforce its, or its licensor\u2019s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Dar\u00e9\u2019s product candidates which could expose its products to competition from other formulations using the same active ingredients; cyber attacks, security breaches or similar events that compromise Dar\u00e9\u2019s technology systems or those of third parties on which it relies and\/or significantly disrupt Dar\u00e9\u2019s business; and disputes or other developments concerning Dar\u00e9\u2019s intellectual property rights. Dar\u00e9\u2019s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Dar\u00e9\u2019s risks and uncertainties, you are encouraged to review its documents filed with the\u00a0SEC\u00a0including Dar\u00e9\u2019s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Dar\u00e9 undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Lisa Walters-Hoffert, Chief Financial Officer <br \/>Dar\u00e9 Bioscience, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uT4VK_RCDYHyxvBYG_TUfX4_Zqn8J6ZbbMR71h-EVpraRbAKAraLJwgoVyswPurTA5XW3xKh_23X82xcQzLW5j-gdTXdy_dZB_Bb7a165i_rMGJdBaZKf6mrs-w8Fcm9\" rel=\"nofollow noopener\" target=\"_blank\">lwalters@darebioscience.com<\/a><br \/>858.926.7655<\/p>\n<p align=\"justify\">Source: Dar\u00e9 Bioscience, Inc.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Dar\u00e9 Bioscience, Inc. and Subsidiaries<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Consolidated Statements of Operations and Comprehensive Loss<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>(Unaudited)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"7\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Three Months Ended<\/strong><br \/>\n            <br \/>\n            <strong>June 30, 2021<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:63%;width:63%;min-width:63%;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: center;vertical-align: middle\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: center;vertical-align: middle\">\n            <strong>2020<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Operating expenses:<\/strong>\n          <\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">General and administrative<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">1,797,637<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">1,557,548<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Research and development expenses<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">7,340,289<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">5,547,450<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">License fees<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">25,000<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">20,833<\/td>\n<td style=\"border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Total operating expenses<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">9,162,926<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">7,125,831<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Loss from operations<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(9,162,926<\/td>\n<td style=\"border-top: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(7,125,831<\/td>\n<td style=\"border-top: solid black 1pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Other income<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">175<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">1,618<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Net loss<\/strong>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(9,162,751<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(7,124,213<\/td>\n<td style=\"border-top: solid black 1pt;border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px\">Foreign currency translation adjustments<\/td>\n<td style=\"border-top: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-top: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(8,880<\/td>\n<td style=\"border-top: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td style=\"border-top: solid black 1pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-top: double black 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-top: double black 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">12,090<\/td>\n<td style=\"border-top: double black 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">\n            <strong>Comprehensive loss<\/strong>\n          <\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(9,171,631<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(7,112,123<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Loss per common share &#8211; basic and diluted<\/td>\n<td style=\"border-top: double black 3pt;border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-top: double black 3pt;border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(0.18<\/td>\n<td style=\"border-top: double black 3pt;border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-top: double black 3pt;border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"border-top: double black 3pt;border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(0.27<\/td>\n<td style=\"border-top: double black 3pt;border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Weighted average number of common shares outstanding:<\/td>\n<td colspan=\"3\" style=\"border-top: double black 3pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: double black 3pt;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 20.0px\">Basic and diluted<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">50,436,593<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-right: 0;text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">26,710,750<\/td>\n<td style=\"border-bottom: double 15px 3pt;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Dar\u00e9 Bioscience, Inc. and Subsidiaries<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\" style=\"text-align: center;vertical-align: middle\">\n            <strong>Condensed Consolidated Balance Sheet Data<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>June 30, 2021<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>December 30, 2021<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>(unaudited)<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-top: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:63%;width:63%;min-width:63%;text-align: left;vertical-align: middle\">Cash and cash equivalents<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">9,111,741<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">4,669,467<\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Working capital (deficit)<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">8,054,330<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(676,689<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Total assets<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">14,822,410<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">7,550,712<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle\">Total stockholders&#8217; equity (deficit)<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">7,744,004<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"padding-right: 0;text-align: right;vertical-align: middle\">$<\/td>\n<td style=\"padding-left: 0;padding-right: 0;text-align: right;vertical-align: middle\">(1,151,733<\/td>\n<td style=\"padding-left: 0;text-align: left;vertical-align: middle\">)<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDAyYTVmZjktYzRkNy00MGRhLTk2MTctZGU5ZTAxMTk2NzFiLTEwMTk5Mzc=\/tiny\/Dar-Bioscience-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conference Call and Webcast Today at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) &#8212; Dar\u00e9\u00a0Bioscience, Inc. (NASDAQ: DARE), a leader in women\u2019s health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update. \u201cThis has been, and continues to be, an incredibly productive year for Dar\u00e9,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cConsistent with our guidance, we submitted our New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June. Our NDA was accepted for filing and received Priority Review with a PDUFA target date of December 7, 2021. This year we also commenced the Phase 2b RESPOND &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-527255","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference Call and Webcast Today at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) &#8212; Dar\u00e9\u00a0Bioscience, Inc. (NASDAQ: DARE), a leader in women\u2019s health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update. \u201cThis has been, and continues to be, an incredibly productive year for Dar\u00e9,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cConsistent with our guidance, we submitted our New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June. Our NDA was accepted for filing and received Priority Review with a PDUFA target date of December 7, 2021. This year we also commenced the Phase 2b RESPOND &hellip; Continue reading &quot;Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-12T12:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update\",\"datePublished\":\"2021-08-12T12:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/\"},\"wordCount\":2227,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/\",\"name\":\"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=\",\"datePublished\":\"2021-08-12T12:03:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/","og_locale":"en_US","og_type":"article","og_title":"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update - Market Newsdesk","og_description":"Conference Call and Webcast Today at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) &#8212; Dar\u00e9\u00a0Bioscience, Inc. (NASDAQ: DARE), a leader in women\u2019s health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update. \u201cThis has been, and continues to be, an incredibly productive year for Dar\u00e9,\u201d said Sabrina Martucci Johnson, President and CEO of Dar\u00e9 Bioscience. \u201cConsistent with our guidance, we submitted our New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June. Our NDA was accepted for filing and received Priority Review with a PDUFA target date of December 7, 2021. This year we also commenced the Phase 2b RESPOND &hellip; Continue reading \"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-12T12:03:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update","datePublished":"2021-08-12T12:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/"},"wordCount":2227,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/","name":"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=","datePublished":"2021-08-12T12:03:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNzQ4NyM0MzU0MDQ5IzIwMDgzNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dare-bioscience-reports-second-quarter-2021-financial-results-and-provides-a-company-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dar\u00e9 Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/527255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=527255"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/527255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=527255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=527255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=527255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}